Drugs / GVAX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02243371 Background | Jan 2015 → Jul 2017 | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243371 ↗ |
| Modality | Vaccine | “GVAX Pancreas Vaccine” NCT02243371 ↗ |
| Route | Other | “5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2” NCT02243371 ↗ |